Alloy Therapeutics Featured Profile: Making Better Medicines by Breaking Down Barriers to Translation
July 30, 2021 | Alloy Therapeutics
Alloy Therapeutics White Paper: Approaches to Binder Recovery Following Immunization Campaigns in Mouse Models
July 29, 2021 | Alloy Therapeutics
Alloy Therapeutics and Echo Investment Capital Create Wheeler Bio to Accelerate the Development of New Antibody Therapeutics
July 21, 2021 | Alloy Therapeutics
Read More: Press Release | Business Wire | The Oklahoman | Science Advisory Board | Journal Record | BioSpace | PEHub
Vernal Biosciences Launches to Democratize Access to High Quality mRNA Manufacturing
July 12, 2021 | Alloy Therapeutics
Read More: Press Release | Business Wire | Vermont Business Wire | Venture Capital Journal | The Science Advisory Board
Alloy Therapeutics and Pyxis Oncology Form Kyma Therapeutics to Develop Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases
May 25, 2021 | Alloy Therapeutics
Read More: Press Release | Business Wire | Fierce Biotech | BioSpace | BioWorld | Boston Business Journal | Endpoionts
Alloy Therapeutics Raises $75 Million in Series C Financing to Advance Collaborative Biotechnology Ecosystem
April 2, 2021 | Alloy Therapeutics
Funds to be used to advance platforms and resources used by scientific entrepreneurs to turn ideas into biological medicines.
Read More: Press Release | Business Wire | Business Insider | Fierce Biotech | Scrip | Wall Street Journal Pro | EndPoints News | Boston Business Journal | Bio Century
Stanford and Alloy Therapeutics Collaborate to Develop Antibody Prototypes for Innovative Medicines Accelerator
March 3, 2021 | Stanford Innovative Medicines Accelerator
Stanford has obtained a worldwide, non-exclusive license to use the immunocompetent Alloy-Gx transgenic mice for in vivo human antibody discovery for research, development, and commercialization.
Evotec Partners with Alloy Therapeutics to Expand its Antibody Discovery Platform
December 21, 2020 | Evotec
Evotec SE and Alloy Therapeutics, a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all, today announced that the companies have entered into a technology partnership to expand Evotec’s antibody discovery platform.
Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies for Genetically Validated Targets in Ophthalmic Diseases
December 7, 2020 | Maze Therapeutics
Maze Therapeutics and Alloy Therapeutics announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases.
Read More: Press Release | Fierce Biotech | Endpoints | SF Business Times
Alloy Therapeutics Becomes BaseLaunch’s First Dedicated Antibody Discovery Domain Partner
November 24, 2020 | BaseLaunch
Alloy Therapeutics joins BaseLaunch’s endeavor to fuel the next generation of exceptional biotechnology companies.
AbCellera Announces Agreement with Alloy Therapeutics to Integrate Access to ATX-Gx™ Humanized Mice Platform for Antibody Discovery Programs
July 21, 2020 | AbCellera
AbCellera announced that it has entered into an agreement with Alloy Therapeutics to use the ATX-Gx™ humanized mice platform to enable best-in-class in vivo human antibody discovery for its partner programs.
US Antibody Ace Leverages Cambridge Base
June 10, 2020 | Business Weekly
Alloy Therapeutics, formed in Massachusetts in 2017, is dedicated to empowering global scientists with foundational drug discovery platforms and services. It is hiring fresh talent at its new UK home at Granta’s McLintock Building.